Choquette, Denis http://orcid.org/0000-0001-6585-7695
Bessette, Louis
Alemao, Evo
Haraoui, Boulos
Postema, Roelien
Raynauld, Jean-Pierre
Coupal, Louis
Funding for this research was provided by:
Bristol-Myers Squibb (NA)
AbbVie (NA)
Amgen (NA)
Celgene (NA)
Eli Lilly (NA)
Merck (NA)
Novartis (NA)
Pfizer (NA)
Roche (NA)
Sanofi (NA)
Sandoz (NA)
UCB (NA)
Article History
Received: 8 October 2018
Accepted: 14 May 2019
First Online: 6 June 2019
Ethics approval and consent to participate
: Rhumadata® is approved on an annual basis by an ethics committee (Institutional Review Board Services, Aurora, Ontario, Canada). All registry subjects were required to provide written informed consent prior to participating.
: Not applicable.
: DC is a consultant and speaker for Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Sandoz. LB is a consultant and speaker for, and has received research support from, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche, and UCB; in addition, LB has received speaker fees from Merck and research support from Merck and Sanofi. EA and RP are employees of and/or shareholders of and/or hold stock options in Bristol-Myers Squibb. BH is a consultant for AbbVie, Amgen, Lilly, Merck, Pfizer, and UCB; in addition, BH is a speaker for Pfizer and has received research support from AbbVie. J-PR is a speaker and consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB; in addition, J-PR has received consulting fees and research support from Arthrovision Inc. LC declares no competing interests.